Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology

Syed Moiz Ahmed and Peter Dröge

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore

Keywords
chemotherapy; DNA topology; HMGA2; replication stress; TOP2

Correspondence
P. Dröge, School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore
Tel: +65 6316 2809
E-mail: pdroge@ntu.edu.sg

(Rceived 19 April 2019, revised 26 June 2019, accepted 3 July 2019, available online 31 August 2019)
doi:10.1002/1878-0261.12541

Rapidly dividing cells maintain chromatin supercoiling homeostasis via two specialized classes of enzymes, DNA topoisomerase type 1 and 2 (TOP1/2). Several important anticancer drugs perturb this homeostasis by targeting TOP1/2, thereby generating genotoxic DNA damage. Our recent studies indicated that the oncofetal chromatin structuring high-mobility group AT-hook 2 (HMGA2) protein plays an important role as a DNA replication fork chaperone in coping with DNA topological ramifications that occur during replication stress, both genomewide and at fragile sites such as sub-telomeres. Intriguingly, a recent large-scale clinical study identified HMGA2 expression as a sole predicting marker for relapse and poor clinical outcomes in 350 acute myeloid leukemia (AML) patients receiving combinatorial treatments that targeted TOP2 and replicative DNA synthesis. Here, we demonstrate that HMGA2 significantly enhanced the DNA supercoil relaxation activity of the drug target TOP2A and that this activator function is mechanistically linked to HMGA2’s known ability to constrain DNA supercoils within highly compacted ternary complexes. Furthermore, we show that HMGA2 significantly reduced genotoxic DNA damage in each tested cancer cell model during treatment with the TOP2A poison etoposide or the catalytic TOP2A inhibitor merbarone. Taken together with the recent clinical data obtained with AML patients targeted with TOP2 poisons, our study suggests a novel mechanism of cancer chemoresistance toward combination therapies administering TOP2 poisons or inhibitors. We therefore strongly argue for the future implementation of trials of HMGA2 expression profiling to stratify patients before finalizing clinical treatment regimes.

1. Introduction

The fine-tuned regulation of DNA/chromatin topology is essential for the maintenance of cellular functions and genome stability. This applies especially to fast proliferating cancer cells which face severe DNA topological challenges during genome replication and other DNA transactions (Droge, 1994; Keszthelyi et al., 2016; Kotsantis, et al., 2018; Wang, 2002). DNA topoisomerase type 1 and 2 (TOP1/2) introduce controlled, transient breaks into chromosomal DNA, thereby resolving DNA/chromatin topological ramifications and promoting DNA transactions such as the progression of replication forks and RNA polymerases (Bermejo et al., 2007; Delgado et al., 2018; Wang, 1985; Zechiedrich and Osheroff, 1990).

Given these crucial cellular functions, a diverse group of anticancer drugs that target human TOP2 are

Abbreviations
AML, acute myeloid leukemia; Dox, doxycycline; DSB, double-strand break; Etop, etoposide; HMGA2, high-mobility group AT-hook 2; Merb, merbarone; scDNA, supercoiled DNA; TOP1/2, topoisomerase 1/2; TOP2cc, TOP2-DNA cleavage complexes.
often administered as the first-line therapy to treat primary as well as metastatic tumors (Hande, 1998a; Hevener et al., 2018; Pommier, 2013; Pommier et al., 2010). Etoposide (Etop) or VP-16 and doxorubicin are the most prescribed TOP2 inhibitors applied alone or in multidrug treatment regimens. Etop is widely used in the treatment of testicular, small cell lung cancers, and lymphomas (Hande, 1998b; Hevener et al., 2018), whereas doxorubicin is often administered to treat acute myeloid leukemia (AML) and several other carcinomas (Burden and Osheroff, 1998; Meredith and Dass, 2016; Tacar et al., 2013).

Most clinically relevant TOP2 inhibitors lead to the formation of covalent TOP2-DNA cleavage complexes (TOP2cc) by preventing religation of the double-strand break (DSB) in otherwise transiently cleaved DNA molecules (Chikamori et al., 2010; Hu et al., 2018; Osheroff, 1989). These inhibitors are collectively called TOP2 ‘poisons’ and cause genomewide DNA strand breaks, for example, during DNA transactions when replisomes or transcription assemblies collide with TOP2cc (Baranello et al., 2014; Pommier et al., 2010; Tammaro et al., 2013; Yan et al., 2016; Yu et al., 2017). TOP2 catalytic inhibitors, for example, merbarone (Merb), do not trap the enzyme in covalent complexes with DNA (TOP2cc), but they also block DNA supercoil relaxation. This class of inhibitors is under clinical evaluation and can induce DNA damage. However, their genotoxic mechanisms of action remain to be elucidated, with inducing DNA replication stress and replication fork collapse as strong candidates (Fortune and Osheroff, 1998; Glover et al., 1987; Larsen et al., 2003; Nitiss, 2009; Pastor et al., 2012; Wang and Eastmond, 2002; Wang et al., 2007).

Although TOP2-targeting anticancer drugs have successfully been administered in the clinic, the treatment outcome per individual patient varies greatly. Hence, a better understanding of cancer cell-autonomous factors which determine their treatment efficacies could have clinical impact. In this context, the high-mobility group AT-hook 2 (HMGA2) protein is known as a nonhistone architectural chromatin factor which has been implicated in carcinogenesis and in particular metastasis (Gao et al., 2017; Morishita et al., 2013; Pallante et al., 2015; Young and Narita, 2007). The protein is not detectable in most adult somatic cells, but HMGA2 is aberrantly expressed during malignant cell transformation, particularly in mesenchymal tumors (Dreux et al., 2010). Its elevated expression in breast cancer (Wu et al., 2016), lung cancer (Sarhadi et al., 2006), colorectal cancer (Wang et al., 2011), oral carcinomas (Miyawaza et al., 2004), and several other malignancies has often been associated with poor clinical treatment outcomes (Wu and Wei, 2013).

High-mobility group AT-hook 2 possesses three independent DNA binding domains, which preferentially recognize AT-rich nucleotide sequences in double-stranded DNA (Pfannkuche et al., 2009; Reeves and Nissen, 1990). Besides important regulatory roles in gene expression, in particular during embryonic/fetal development and tumorigenesis/metastasis in the adult organism (Droge and Davey, 2008; Fusco and Fedele, 2007; Pfannkuche et al., 2009; Sgarra et al., 2018), HMGA2 has also been implicated in DNA base excision repair (Summer et al., 2009) and DNA damage repair signaling pathways (Hombach-Klonisch et al., 2019; Natarajan et al., 2013; Palmieri et al., 2011), hinting at important functions for HMGA2 in genome stability following genotoxic stress conditions. In this context, fast proliferation rates of cancer cells enhance DNA replication stress (Gaillard et al., 2015), and we have recently demonstrated that HMGA2 broadly protects hydroxyurea (HU)-induced stalled replication forks from collapse into genotoxic DSBs in human cancer and stem cells, thus implying that HMGA2 is also involved upstream of DNA repair processes as a first line of defense to prevent genome instability (Ahmed et al., 2019; Yu et al., 2014).

High-mobility group AT-hook 2, by means of its three AT-hook DNA binding domains, forms unique complexes with supercoiled DNA (scDNA), thereby curbing excess topological stress via constrainment of scDNA (Ahmed et al., 2019; Peter et al., 2016; Zhao et al., 2017). Intriguingly, depending on the relative HMGA2 expression levels in various cancer cell models, HMGA2 either triggered or attenuated the genotoxic action of the clinically important TOP1 poison irinotecan/SN38, specifically at heterochromatic subtelomeres (Ahmed et al., 2019). The sensitizing effect of low-to-moderate HMGA2 expression to irinotecan treatment was also demonstrated in patient-derived xenograft models of human colon cancer, and we mechanistically ascribed these outcomes to a potentiating drug effect in ternary scDNA-TOP1-HMGA2 complexes. Collectively, these data led to a new model in which HMGA2 plays an important role in cancer genome stability at topologically challenged chromatin regions, such as replication forks and subtelomeres (Ahmed et al., 2019; Zhao et al., 2017).

Here, we show that the expression of HMGA2 confers broad protection to cancer cells treated with the clinically important TOP2-targeting drugs Etop and Merb, leading to a significant reduction in genotoxic DSBs during the course of drug treatment. We propose that the DNA topological stress generated through the drug-induced
catalytic inhibition and/or the trapping of TOP2 with DNA in chromatin is counteracted by HMGA2 via a combination of TOP2 catalytic activation and DNA supercoil constraint. Importantly, our proposed model provides a plausible mechanistic explanation for the results of a recently published clinical study (Marquis et al., 2018) with more than 350 AML patients who were treated with TOP2 poisons in combination with the DNA synthesis inhibitor cytarabine (Ara-C) as first-line combination therapy. The clinical data revealed that HMGA2 expression in leukemic cells in vivo is an independent negative predictor of disease relapse and patient survival (Marquis et al., 2018). Taken together with our previous HMGA2 studies investigating TOP1 poisons and DNA synthesis inhibitors (Ahmed et al., 2019; Yu et al., 2014), our current study strongly enforces the clinical importance of HMGA2 as a prognostic therapeutic marker in the clinic and as an important drug target.

2. Materials and methods

2.1. Cell culture

All cancer cell line model systems were cultured according to ATCC recommendations. Recombinant HT1080 C1/C2 cells expressing doxycycline (Dox) hydrolase (Sigma, Singapore) inducible shHMGA2 were generated as described previously (Yu et al., 2014), and HMGA2 knockdown was achieved with Dox treatment once every day for 4 days. Human HMGA2-expressing clones A549 (1.3/1.5/1.6) and HeLa (P2/P8/P19) have been described previously (Summer et al., 2009). H1299 HMGA2 KO cells were generated by CRISPR-Cas9 and have also been described previously (Ahmed et al., 2019).

2.2. Western blotting

Protein lysates were prepared as detailed previously (Ahmed et al., 2019). Briefly, cells were resuspended in RIPA buffer containing Protease Inhibitor cocktail (Roche, Basel, Switzerland) on ice. The mixture was then centrifuged at 15,000 r.p.m. for 20 min at 4 °C. The supernatant was collected, and following protein concentration determination, lysates were separated by SDS/PAGE, transferred onto 0.2-µm PVDF membranes (Bio-Rad, Hercules, CA, USA) and blocked in superblock blocking buffer (Thermo Fisher Scientific, Waltham, MA, USA). Membranes were incubated with primary antibodies [α-HMGA2 (CST 5269; 1:1000; RRID:AB_10694917), α-TOP2A (TopoGEN TG2011-1; 1:2000; RRID:AB_1934304), α-TOP2B (Ab109524; 1:2000; RRID:AB_10859793), α-β-actin (Sigma A2228; 1:5000; RRID:AB_476697)] overnight at 4 °C, followed by incubation with secondary antibodies [Polyclonal goat antiserum mouse (Dako, P0447, Carpinteria, CA, USA; RRID:AB_2617137) and polyclonal goat anti-rabbit (Dako, P0448; RRID:AB_2617138)] at room temperature for 1 h. Immunoreactivity was developed by chemiluminescent HRP substrate (Millipore, Singapore) in a luminescence imager (LAS4000; Fujifilm, Pittsburgh, PA, USA).

2.3. Pulsed-field gel electrophoresis (PFGE) and Southern blotting

Our pulsed-field gel electrophoresis (PFGE) assay conditions have been described previously (Ahmed et al., 2019). Briefly, 0.4 × 10⁶ cells were seeded in a six-well tissue culture plate and treated with indicated doses of Etop (Sigma) for 24 h and Merb (Santa Cruz Biotechnology, Dallas, TX, USA) for 48 h, respectively. 48 h drug treatment involved media replacement with fresh
drug added every 24 h. DMSO-treated cells were used as control. Harvested cells were embedded in 2% low melting agarose (Sigma) plucks followed by incubation in lysis buffer (0.2% sodium deoxycholate, 1% sodium lauroyl sarcosine, 100 mM EDTA, and 1 mg mL⁻¹ protease K) at 50 °C for 24 h. Plugs were washed four times in TE buffer for 1 h each and electrophoresed through 1% megabase agarose (Bio-Rad) on CHEF DR II (Bio-Rad). Lambda PFG ladder (NEB, Ipswich, MA, USA) that ranges from 48.5 to 1018 kb was used as a marker. Subsequently, PFGE gels were stained with ethidium bromide, and quantification was performed using IMAGEJ software, as described in detail in Figure legends. Following PFGE, telomeric DNA was detected by Southern blotting using TeloTAGGG Telomere Length Assay kit (Roche, 12209136001) as per the manufacturer’s protocol and previously detailed in (Ahmed et al., 2019).

2.4. In vitro Etop-induced DNA cleavage assay

Indicated amounts of Etop (Sigma) diluted in DMSO were incubated with 100 ng of supercoiled Renilla reporter plasmid (Peters et al., 2016) in a buffer containing 10 mM Tris/HCl, pH 7.9, 50 mM KCl, 50 mM NaCl, 5 mM MgCl₂, 0.1 mM EDTA, 1 mM ATP, 15 µg mL⁻¹ BSA. The DNA supercoil relaxation reactions were initiated by adding 4.5 U of human recombinant TOP2A (Affymetrix, Santa Clara, CA, USA) to each sample. Reactions were stopped after 30 min at 37 °C with 0.3% (w/v) SDS followed by proteinase K (Thermo Scientific) digestion for 20 min at 37 °C. Samples were analyzed on 0.8% agarose gels and visualized with ethidium bromide staining under UV.

2.5. In vitro HMGA2 DNA relaxation assay

One hundred nanogram of supercoiled plasmid DNA was incubated with different amounts of either purified wild-type HMGA2 or 2.3 AT-hook mutant HMGA2 protein and 0.12 U of human TOP2A (Affymetrix) for 30 min at 37 °C in a buffer containing 10 mM Tris/HCl, pH 7.9, 50 mM KCl, 50 mM NaCl, 5 mM MgCl₂, 0.1 mM EDTA, 1 mM ATP, 15 µg mL⁻¹ BSA. In test runs, we had first established that 0.12 U of human TOP2A achieved partial DNA relaxation in the absence of HMGA2, hence allowing us to investigate catalytic activation functions. Reactions were stopped with 0.3% (w/v) SDS followed by proteinase K digestion. Samples were electrophoresed overnight on a 0.8% agarose gel and visualized under UV by staining with ethidium bromide.

2.6. Complementation assay

4 × 10⁵ HeLa cells were seeded in a six-well plate. DNA transfection was done using lipofectamine 2000 (Invitrogen, 11668-019, Carlsbad, CA, USA) as per the manufacturer’s instructions. pEF1/Myc-A-hmga2-FLAG was used for expression of wild-type HMGA2, whereas pEF1/Myc-A-hmga2-hook2/3Mutant-FLAG was used to express 2,3hook HMGA2 mutant, with pEF1/Myc-A used as mock control. Thirty-six hours post-transfection, cells were exposed to Etop for 24 h followed by analysis of DSBs by PFGE as described in section 2.3. All transfected plasmids have been described previously (Yu et al., 2014).

2.7. Cell survival assay

Cells were seeded as triplicates in a 96-well black/clear bottom plate for each condition and 12 h later treated with indicated doses of Etop/Merb for 48 h. The drug treatment involved media replacement with fresh drug added every 24 h. Cell viability was determined using the CCK-8 assay (Enzo Life Sciences, ALX-850-039-0100, Singapore) as per the manufacturer’s instructions. Briefly, 10 µL of CCK-8 solution is directly added to each well of the plate and incubated for 2 h at 37 °C. Absorbance was measured at 450 nm using microplate reader (TECAN Infinite M200 Pro, Tecan Trading AG,
Role of HMGA2 in TOP2-targeted chemotherapy
confirmed a specific protective function of HMGA2 against Etop-induced DNA breaks (Fig. 1E). This complementation assay also included a variant HMGA2 protein in which two (i.e., AT-hooks 2 and 3) of the three individual DNA binding domains of HMGA2 carried amino acid substitutions (2,3M HMGA2) that reduced their binding affinities to DNA (Yu et al., 2014). This variant HMGA2 failed to complement the lack of wild-type HMGA2 in HeLa cells. These results highlighted that DNA binding via HMGA2’s AT-hooks is critical for its protective function against Etop (Fig. 1E). To validate our results, we utilized cell viability assays and found that expression of HMGA2 correlated with increased cell survival during Etop treatment in all four cancer cell models (Fig. 2A–E).

3.2. HMGA2 does not affect TOP2 expression

With higher TOP levels being potentially accountable for enhanced drug sensitivity (Burgess et al., 2008; MacGrogan et al., 2003; Sevim et al., 2011), we determined whether differential expression of TOP2A and TOP2B, the two major isoforms of human TOP2, might be regulated by HMGA2 and thus could be responsible for the Etop treatment outcome. Western blot analysis revealed that the observed protective effect was not due to changes in TOP2A/B expression levels that consistently correlated with HMGA2 levels (Fig. 3A–D). To corroborate this conclusion, we performed transient transfection experiments and complemented HeLa cells with wild-type or the 2,3M HMGA2 variant and observed no corresponding changes in TOP2A/B expression compared to mock-transfected controls (Fig. 3E). Furthermore, Etop treatment of H1299 cells did not alter the expression level of HMGA2, hence ruling out drug-induced HMGA2 expression changes as a cause for the protective phenotypes (Fig. 3F).

Etop traps and stabilizes covalent TOP2cc, which can be converted into DSBs during replication runoff events (McClendon and Osheroff, 2007; Tammaro et al., 2013; Yan et al., 2016). We confirmed that our batch of the Etop drug is active in inducing TOP2cc formation by using supercoiled plasmid DNA and recombinant human TOP2A in in vitro DNA supercoil relaxation assays. Titration of various concentrations of the drug revealed that plasmid DNA linearization due to the formation of TOP2cc is induced at Etop concentrations used in our cell-based assays (i.e., 10–30 μM; Fig. 3G). Collectively, these data suggest that HMGA2 attenuates DSB formation and cell death triggered by Etop and that DNA binding of HMGA2 is critical for this function.
3.3. HMGA2 counteracts topological stress at human subtelomeres and catalytically activates TOP2A

We next explored the possibility of a more direct role for HMGA2 in regulating topological stress when TOP2 is inhibited rather than ‘poisoned’. We utilized Merb, a catalytic inhibitor of TOP2 that does not stabilize cleavage complexes (TOP2cc) that would result in replication (transcription) runoff at lesions to generate DSBs, but negatively affects the supercoil relaxation activity of TOP2 (Burden and Osheroff, 1998; Chen and Beck, 1995; Tripathi et al., 2019; Zhang et al., 2017). It has been argued that Merb causes
DNA damage by fork stalling and collapse as a result of the buildup of DNA superhelical tension in the unreplicated parental DNA (Fortune and Osheroff, 1998; Wang et al., 2007). Upon Merb treatment, PFGE revealed DNA damage profiles (30–100 kb and > 1 Mb) in all tested cancer cell models which are very similar to those induced by Etop (Fig. 4A–C and Fig. S2A). It appears,
therefore, that excessive topological stress that results from the catalytic inhibition of TOP2 leads to DSBs which are similar to those generated by TOP2cc formation (McClendon and Osheroff, 2007; Tammaro et al., 2013). Importantly, HMGA2 expression protected cells against Merb-induced DSBs with a concomitant significant increase in cell survival (Fig. 5A–D).

Fig. 5. Effects of HMGA2 expression on cancer cell viability after Merb treatment ex vivo. Cell viability (CCK8) assay with (A) H1299 (parental and HMGA2 knockout cells), (B) HeLa (parental and HMGA2 expressing cell clone P2), (C) A549 (parental and HMGA2 expressing cell clone 1.3), and (D) HT1080 C1 (Dox−/Dox+ treated) cells after treatment with two different doses of Merb, as indicated, for 48 h (n = 2 independent experiments with 3 technical replicates for each experiment). (A–D) Unpaired two-tailed t-tests. Error bars, SD. **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant.

Fig. 6. HMGA2 protects subtelomeric domains against TOP2-induced DNA damage. (A) Southern blot with telomere-specific probe for DNA from H1299 cells (parental and HMGA2 KO cells) analyzed by PFGE after treatment with 30 μM Etop for 24 h. See Fig. 1C for the corresponding EtBr stained PFGE image. (B) Southern blot with telomere-specific probe of HeLa cells (parental and HMGA2 expressing cell clone P2) analyzed by PFGE after treatment with three doses of Merb for 48 h.

We have previously demonstrated that human subtelomeres are highly sensitive to inhibition of DNA replication triggered by the ribonucleotide reductase inhibitor HU, TOP1 poisoning by irinotecan (SN38), and the drug TMPyP4; the latter is thought to induce replication fork stalling by stabilizing so-called G-quadruplex DNA secondary structures. We proposed
that subtelomeric regions were highly vulnerable to these genotoxic challenges due, at least in part, to strong DNA topological barriers located at human telomeres (Ahmed et al., 2019). We therefore investigated whether targeting TOP2 with Etop and Merb also triggers DSBs at human subtelomeres. Southern blot analysis using telomeric DNA-specific probes revealed similar fragment profiles that range from 30 to 100 kb (Fig. 6A–B). Based on our previous detailed analysis of the genomic DNA breakpoints leading to 30–100 kb subtelomeric DNA fragments (Ahmed et al., 2019), these data strongly suggest that human subtelomeres are also cellular targets of TOP2 poisons and catalytic TOP2 inhibitors. Furthermore, these data corroborate our model that implicates a critical protective function for HMGA2 in regulating chromatin topological stress at these fragile genomic regions (Ahmed et al., 2019).

Our recent studies showed that HMGA2 formed unique higher order complexes with scDNA in vitro and that within these ternary complexes, HMGA2 juxtaposes DNA segments into closer proximity to each other (Peter et al., 2016; Zhao et al., 2017). These results, in conjunction with the observed protective effect of HMGA2 against the catalytic inhibitor Merb, led us to investigate whether HMGA2 could catalytically activate TOP2A leading to more efficient supercoil relaxation. Because there is currently no reliable assay available that can directly determine DNA supercoil relaxation rates by TOPs inside cells, we employed standard TOP activity in vitro assays to address this question quantitatively.

We found that during 30 min incubation with scDNA, HMGA2 greatly enhanced the relaxation activity of TOP2A, probably by promoting more productive TOP2A-scDNA interactions at DNA crossings via DNA segment scrunching (Zechiedrich and Osheroff, 1990; Zhao et al., 2017) (Fig. 7). This conclusion was strongly supported by results obtained with the 2,3M HMGA2 variant that harbored one instead of three functional AT-hooks (Fig. 7). By employing this HMGA2 variant, we have previously shown that at least two functional AT-hooks are required for efficient supercoil scrunching (Zhao et al., 2017). Taken together, these data reveal that HMGA2 can attenuate the DNA damaging and cytotoxic effects of TOP2A poisons as well as of catalytic inhibitors in various cancer cells, and suggest that these protective effects may be triggered by DNA supercoil scrunching, and catalytic activation of TOP2A in the chromatin of cancer cells that express HMGA2.

4. Discussion

Topoisomerases 1/2 resolve topological ramifications in chromatin through controlled changes in the DNA linking number employing two distinct catalytic mechanisms. Interestingly, several chromatin/DNA architectural proteins have recently been implicated in TOP functions by stimulating DNA supercoil relaxation activity of TOPs (Guo et al., 2018; Stros et al., 2007; Stros et al., 2009). In addition, several tumor-associated proteins such as YB-1 (Wu et al., 2014), p53 (Gobert et al., 1996) (Kwon et al., 2000) and ARF (Karayan et al., 2001) have been shown to enhance TOP activity either through direct protein–protein interactions or by enhancing TOP2 ATPase activity. Such findings could aid in our understanding of cellular chemoresistance that is often observed in cancer.
cells targeted with TOP poisons (Bansal et al., 2017; Ganapathi and Ganapathi, 2013). In this context, our current study uncovered that HMGA2 is a crucial factor that can affect TOP2A function.

TOP2A plays a particularly important role during DNA replication in fast proliferating cells (Heck and Earnshaw, 1986; Hsiang et al., 1988; Marinello et al., 2018; Yan et al., 2016), and while TOP2 poisons, such as Etop, are extensively utilized in clinical practice either as single agents or in combination therapy, the development of secondary tumors is still a major complication. Additionally, treatment efficacy depends on TOP2 expression and drug efflux pumps in cancer cells, thereby hampering their effectiveness as anticancer agents (Felix et al., 2006; Nitiss, 2009; Ratain and Rowley, 1992; Vassetzky et al., 1995).

Our ex vivo results presented in this study provide novel mechanistic insights into the regulation of TOP2-mediated DNA damage and point at HMGA2 as a crucial factor in chemotherapeutic responses following exposure to TOP2 antagonists. Importantly, an extensive recent clinical study that included samples from more than 350 human de novo AML patients treated with TOP2 poisons alone or in combination with DNA synthesis inhibitors implicated HMGA2 expression in leukemic cells to poor clinical outcomes (Marquis et al., 2018). These results were further validated in more than 250 patients, thus highlighting its clinical significance (Marquis et al., 2018). Importantly, these clinical data directly correlate with our ex vivo findings clearly revealing a protective role for HMGA2 against TOP2A targeting drugs and, taken together, illustrates their importance for clinical strategies in particular for HMGA2-positive AML patients.

With more than 60% of AML patients succumbing to leukemia-related issues, and with high HMGA2 expression correlating to poor survival in both the experimental and validation groups (Marquis et al., 2018), we postulate here that resistance to treatment is, at least in part, due to both HMGA2’s ability to catalytically activate TOP2A and to serve as replication fork chaperone during induced replication stress.

**Fig. 8.** Model of the role of HMGA2 in protection of replication forks at subtelomeres against TOP2 targeting drugs. (A) In the absence of HMGA2, TOP2 inhibition by either Merb or Etop generates high levels of (+) supercoiled (sc) DNA ahead of the replication fork or an increase in TOP2cc formation, leading to frequent fork collapse and replication runoff events, respectively. (B) HMGA2 constrains (+) sc DNA and activates TOP2A within transient ternary complexes to relax (+) sc DNA, thus preventing fork collapse/DSBs.
using DNA synthesis inhibitors; the latter role for HMGA2 has been demonstrated previously in other cancer cell models (Ahmed et al., 2019; Yu et al., 2014). More than 70% of AML patients with elevated HMGA2 expression levels experienced relapse after complete remission. Bone marrow-derived mononuclear cells that were tested positive for high HMGA2 expression (Marquis et al., 2018) comprise of a myriad of cells at different stages of maturation, with hematopoietic stem (HPS) cells playing a central role in the development of AML (Corces et al., 2017; Cuende et al., 2012; Sanchez-Aguilera and Mendez-Ferrer, 2017). Importantly, HMGA2 is found to be expressed in human HPS and progenitor cells and serves an important function in proliferation and maintenance of cellular multipotency (Copley et al., 2013; Kumar et al., 2019). A protective function against TOP2-targeting drugs in transformed HPS cells, as exemplified in our current study with various other cancer cell models, as well as the HMGA2-mediated protection against DNA synthesis inhibitors such as HU (Ahmed et al., 2019; Yu et al., 2014), could therefore be critical factors for the increased occurrence of AML relapse.

We identified that fragile sites such as subtelomeres (Sfeir et al., 2009) are susceptible to DNA topological challenges generated by TOP2 inhibition and found that subtelomere instability is also influenced by HMGA2, hence corroborating our previous study which investigated TOP1 poisons and HU (Ahmed et al., 2019). Interestingly, the recently discovered bacterial chromosome factor GapR contributes to genome stability especially during fast replication cycles through DNA supercoil constrainment and activation of gyrase (a bacterial TOP2) within transient DNA–protein ternary complexes (Guo et al., 2018). We propose here a very similar role for HMGA2 and TOP2A which protects subtelomeric and other human genomic regions against induced, unscheduled fork stalling/collapse and chromosomal breakage. In cells lacking HMGA2, treatment with Etop will enhance the occurrence of TOP2cc formation downstream of replication forks and results in frequent replication runoff events and genotoxic DNA damage that releases telomeric DNA fragments (Fig. 8A). This model is supported by the results from a recent study that demonstrated human TOP2 facilitates telomere replication and that TOP2 poisoning leads to excised telomeric DNA circles as a result of replication fork runoff/collapse (Zhang et al., 2017). Treatment with the catalytic inhibitor Merb, on the other hand, will primarily lead to excess of (+) supercoiling downstream of progressing forks, which, in turn, promotes fork stalling and collapse into genotoxic DSBs following nucleolytic attack (Fig. 8A). Interestingly, a recent study showed that inhibition of the catalytic activity of TOP2A leads to telomere fragility during mitosis, most likely through the formation of unresolved catenated DNA between sister chromatids (d’Alcontres et al., 2014). In cancer cells expressing HMGA2, we propose that the protein mitigates the effects of both TOP2 targeting drugs by a combination of DNA supercoil constrainment and TOP2A catalytic activation, hence acting as a DNA supercoil ‘sink’ (Fig. 8B).

Our in vitro results obtained with the HMGA2 variant that carries substitutions in AT-hooks 2 and 3 imply that the supercoil constrainment could directly lead to the catalytic activation of TOP2. However, this does not exclude that this catalytic activation function may also be mediated by direct HMGA2-TOP2 physical interactions, as identified through a HMGA2 interactome study using mouse cells (Singh et al., 2015). Such protein–protein interaction would aid TOP2 to more efficiently recognize and associate with relevant regions in supercoiled substrates such as AT-rich nuclear matrix attachment sites within a highly compacted and entangled chromatin. This scenario is also supported by studies that demonstrated chromatin colocalization between HMGA proteins and TOP2 (Martelli et al., 1998; Reeves, 2010; Saitoh and Laemmli, 1994).

Our study revealed that the catalytic inhibitor Merb that does not lead to the formation of TOP2cc generates DNA damage profiles similar to those observed with TOP2 poisons, implying that excess topological stress alone due to an overall reduced intracellular TOP2 activity can cause genotoxic DNA damage. Based on the very similar DNA damage profiles that we observed after inhibiting DNA synthesis by HU (Ahmed et al., 2019; Yu et al., 2014), we think that the collapse of stalled replication forks triggered by unresolved DNA topological stress could be a more frequent cause for the genotoxic effects of these different and clinically relevant drugs. This contests the widely accepted notion that the formation of protein–DNA adducts (TOP2cc) on the parental strands and subsequent collision with replisomes is solely responsible for fork collapse and a major contributor to DSBs and genome instability (Larsen et al., 2003; Nadas and Sun, 2006).

Our current study investigated a role of HMGA2 in the induction of DNA lesions during the course of genotoxic drug treatment. However, HMGA2 has recently also been implicated in DNA damage repair signaling pathways, thus hinting at important functions in genome stability that act downstream of the formation of DNA lesions (Hombach-Klonisch et al., 2019).
5. Conclusions

In conclusion, the attenuation of genotoxic DSBs during Etop or Merb treatment in the presence of HMGA2 highlights its role in regulating DNA/chromatin topological stress genomewide and especially at fragile subtelomeric regions. The latter are prone to replication fork stalling due to their heterochromatic nature, terminal position, and the potential formation of DNA topological barriers in form of T-loops (Cubiles et al., 2018; Martinez and Blasco, 2015). This suggests a novel mechanism of chemoresistance toward combination therapies involving TOP2 poisons/inhibitors and strongly argues for HMGA2 expression profiling to aid therapy decision making, in particular in AML patients.

Acknowledgements

We thank Roland Ivanyi-Nagy and Priya Dharshana for the help in statistical data analysis and discussions. This research was supported by Singapore Ministry of Education Academic Research Fund Tier 3 (MOE2012-T3-1-001 to PD).

Conflict of interest

The authors declare no conflict of interest.

Data accessibility

The datasets for this study including raw data files for all figures along with supplementary material can be found on Mendeley dataset at: https://data.mendeley.com/datasets/fnztsz6zh/draft?a=76385a4f-81bd-4fa9-b9fe-4cebe04ff8042

Author contributions

SMA and PD designed the study. SMA performed the experiments and analyzed the data. SMA and PD wrote the manuscript. PD supervised and obtained funding for the study.

References

Ahmed SM, Ramani PD, Wong SQR, Zhao X, Ivanyi-Nagy R, Leong TC, Chua C, Li Z, Hentze H, Tan IB et al. (2019) The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity. *PLoS ONE* 14, e0215696.

Bansal S, Bajaj P, Pandey S and Tandon V (2017) Topoisomerasases: Resistance versus sensitivity, how far can we go? *Med Res Rev* 37, 404–438.

Baranello L, Kozuline F, Wojtowicz D, Cui K, Przytycka TM, Zhao K and Levens D (2014) DNA break mapping reveals topoisomerase II activity genomewide. *Int J Mol Sci* 15, 13111–13122.

Burden DA and Osheroff N (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. *Biochim Biophys Acta* 1400, 139–154.

Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW and Hemann MT (2008) Topoisomerase levels determine chemotherapy response *in vitro* and *in vivo*. *Proc Natl Acad Sci USA* 105, 9053–9058.

Chen M and Beck WT (1995) Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. *Cancer Res* 55, 1509–1516.

Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R and Ganapathi MK (2010) DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. *Curr Cancer Drug Targets* 10, 758–771.

Copley MR, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, Wohrer S, Trelor DQ, Day C, Rowe K et al. (2013) The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. *Nat Cell Biol* 15, 916–925.

Corces MR, Chang HY and Majeti R (2017) Preleukemic hematopoietic stem cells in human acute myeloid leukemia. *Front Oncol* 7, 263.

Cubiles MD, Barroso S, Vaquero-Sedas MI, Enguix A, Aguilera A and Vega-Palas MA (2018) Epigenetic features of human telomeres. *Nucleic Acids Res* 46, 2347–2355.

Cuenne N, Rico L and Herrera C (2012) Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation? *Stem Cells Transl Med* 1, 403–408.

d’Alcontres MS, Palacios JA, Mejias D and Blasco MA (2014) Topo1alpha prevents telomere fragility and...
formation of ultra thin DNA bridges during mitosis through TRF1-dependent binding to telomeres. Cell Cycle 13, 1463–1481.

Delgado JL, Hsieh CM, Chan NL and Hiasa H (2018) Topoisomerases as anticancer targets. Biochem J 475, 373–398.

Dreux N, Marty M, Chibon F, Velasco V, Hostein I, Ranchere-Vince D, Terrier P and Coindre JM (2010) Value and limitation of immunohistochemical expression of HMGA2 in mesenchymal tumors: about a series of 1052 cases. Mod Pathol 23, 1657–1666.

Droge P (1994) Protein tracking-induced supercoiling of DNA: a tool to regulate DNA transactions in vivo? BioEssays 16, 91–99.

Droge P and Davey CA (2008) Do cells let-7 determine stemness? Cell Stem Cell 2, 8–9.

Felix CA, Kolaris CP and Osheroff N (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) 5, 1093–1108.

Fortune JM and Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase Halph by blocking DNA cleavage. J Biol Chem 273, 17643–17650.

Fusco A and Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7, 899–910.

Gaiard H, Garcia-Muse T and Aguilera A (2015) Replication stress and cancer. Nat Rev Cancer 15, 276–289.

Ganapathi RN and Ganapathi MK (2013) Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol 4, 89.

Gao X, Dai M, Li Q, Wang Z, Lu Y and Song Z (2017) HMGA2 regulates lung cancer proliferation and metastasis. Thorac Cancer 8, 501–510.

Glover A, Chun HG, Kleinman LM, Cooney DA, Plowman J, Grieshaber CK, Malspeis L and Leyland-Jones B (1987) Merbarone: an antitumor agent entering clinical trials. Invest New Drugs 5, 137–143.

Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, Larsen AK and Riou JF (1996) Modulation of DNA topoisomerase I activity by p53. Biochemistry 35, 5778–5786.

Guo MS, Haakonsen DL, Zeng W, Schumacher MA and Laub MT (2018) A bacterial chromosome structuring protein binds overtwisted DNA to stimulate type II topoisomerases and enable DNA replication. Cell 175, 583–597, e523.

Hande KR (1998a) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400, 173–184.

Hande KR (1998b) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34, 1514–1521.

Heck MM and Earnshaw WC (1986) Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103(6 Pt 2), 2569–2581.

Hevener K, Verstak TA, Lutat KE, Riggsbee DL and Mooney JW (2018) Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharm Sin B 8, 844–861.

Hombach-Klonisch S, Kalantari F, Medapati MR, Natarajan S, Krishnan SN, Kurnar-Kanojia A, Thanasupawat T, Begum F, Xu FY, Hatch GM et al. (2019) HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells. Mol Oncol 13, 153–170.

Hsiang YH, Wu HY and Liu LF (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48, 3230–3235.

Hu W, Huang XS, Wu JF, Yang L, Zheng YT, Shen YM, Li ZY and Li X (2018) Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches. J Med Chem 61, 8947–8980.

Karayan L, Riou JF, Seite P, Migeon J, Cantereau A and Larsen CJ (2001) Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20, 836–848.

Keshthelyi A, Minchell NE and Baxter J (2016) The causes and consequences of topological stress during DNA replication. Genes 7, 134.

Kotsantis P, Petermann E and Boulton SJ (2018) Mechanisms of oncogene-induced replication stress: jigsaw falling into place. Cancer Discov 8, 537–555.

Kumar P, Beck D, Galeev R, Thoms JAI, Talkhoncheh MS, de Jong I, Unnikrishnan A, Baudet A, Subramaniam A, Pimanda JE et al. (2019) HMGA2 promotes long-term engraftment and myeloerythroid differentiation of human hematopoietic stem and progenitor cells. Blood Adv 3, 681–691.

Kwon Y, Shin BS and Chung IK (2000) The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase Halph by enhancing the rate of ATP hydrolysis. J Biol Chem 275, 18503–18510.

Larsen AK, Escargueil AE and Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99, 167–181.

MacGrogan G, Rudolph P, Mascarel Id I, Mauriac L, Rudolph P, Mascarel Id I, Mauriac L, Martelli AM, Riccio M, Bareggi R, Manfioletti G, Tabellini G, Baldini G, Narducci P and Giancotti V.
(1998) Intranuclear distribution of HMG1/Y proteins. An immunocytochemical study. J Histochem Cytochem 46, 863–864.

Martinez P and Blasco MA (2015) Replicating through telomeres: a means to an end. Trends Biochem Sci 40, 504–515.

McCleland AK and Osheroff N (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 623, 83–97.

McCleland AK, Rodriguez AC and Osheroff N (2005) Human topoisomerase Ialpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks. J Biol Chem 280, 39337–39345.

Meredith AM and Dass CR (2016) Increasing role of the molecular oncology.

Miyazawa J, Mitoro A, Kawashiri S, Chada KK and Imai (2019) 2062–2078

Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szaboles M, Okada Y, D’Armiento J and Chada K (2013) HMG2 is a driver of tumor metastasis. Cancer Res 73, 4289–4299.

Nadas J and Sun D (2006) Anthracyclines as effective anticancer drugs. Expert Opin Drug Discov 1, 549–568.

Natarajan S, Hombuch-Klönisch S, Droge P and Klönisch T (2013) HMG2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia 15, 263–280.

Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9, 338–350.

Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/relation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28, 6157–6160.

Pallante P, Sepe R, Puca F and Fusco A (2015) High mobility group a proteins as tumor markers. Front Med (Lausanne) 2, 15.

Palmieri D, Valentino T, D’Angelo D, De Martino I, Pastor N, Dominguez I, Orta ML, Campanella C, Mateos S and Cortes F (2012) The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res 738–739, 45–51.

Peter S, Yu H, Ivanji-Nagy R and Droge P (2016) Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I. Nucleic Acids Res 44, e162.

Pfannkuche K, Summer H, Li O, Hescheler J and Droge P (2009) The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev 5, 224–230.

Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8, 82–95.

Pommier Y, Leo E, Zhang H and Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17, 421–433.

Pommier Y, Sun Y, Huang SN and Nitiss JL (2016) Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol 17, 703–721.

Ratain MJ and Rowley JD (1992) Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 3, 107–111.

Reeves R (2010) Nuclear functions of the HMG proteins. Biochim Biophys Acta 1799, 3–14.

Reeves R and Nissen MS (1990) The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265, 8573–8582.

Saitoh Y and Laemmli UK (1994) Metaphase chromosome structure: bands arise from a differential folding path of the highly AT-rich scaffold. Cell 76, 609–622.

Sanchez-Aguilera A and Mendez-Ferraz S (2017) The hematopoietic stem-cell niche in health and leukemia. Cell Mol Life Sci 74, 579–590.

Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S (2006) Increased expression of high mobility group A proteins in lung cancer. J Pathol 209, 206–212.

Sevim H, Parkinson JF and McDonald KL (2011) Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha? J Cancer Res Clin Oncol 137, 1705–1712.

Sfeir A, Kosiyatrkul ST, Hockemeyer D, MacRae SL, Karlseder J, Schildkraut CL and de Lange T (2009) Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell 138, 90–103.

Sgarra R, Pegoraro S, Ros G, Penzo C, Chieffari E, Foti D, Brunetti A and Manfioletti G (2018) High mobility group A (HMGA) proteins: molecular instigators of breast cancer onset and progression. Biochim Biophys Acta Rev Cancer 1869, 216–229.

Singh I, Ozturk N, Cordero J, Mehta A, Hasan D, Cosentino C, Sebastian C, Kruger M, Looso M, Carraro G et al. (2015) High mobility group protein-mediated transcription requires DNA damage marker gamma-H2AX. Cell Res 25, 837–850.

Stros M, Bacíkova A, Polanska E, Stokrova J and Strauss F (2007) HMGB1 interacts with human topoisomerase Ialpha and stimulates its catalytic activity. Nucleic Acids Res 35, 5001–5013.
Role of HMGA2 in TOP2-targeted chemotherapy

S. M. Ahmed and P. Dröge

Stros M, Polanska E, Struncova S and Pospisilova S (2009) HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase HalpHa. *Nucleic Acids Res* 37, 2070–2086.

Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, Henderson D, Klonisch T, Goodman SD and Droge P (2009) HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. *Nucleic Acids Res* 37, 4371–4384.

Tacar O, Srimornsak P and Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. *J Pharm Pharmacol* 65, 157–170.

Tammaro M, Barr P, Ricci B and Yan H (2013) Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide. *PLoS ONE* 8, e79202.

Tripathi N, Ghuchhait SK and Bharatam PV (2019) Pharmacoinformatics analysis of merbarone binding site in human topoisomerase HalpHa. *J Mol Graph Model* 86, 1–18.

Vassetzky YS, Alghisi GC and Gasser SM (1995) DNA topoisomerase II mutations and resistance to anti-tumor drugs. *BioEssays* 17, 767–774.

Wang JC (1985) DNA topoisomerases. *Annu Rev Biochem* 54, 665–697.

Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. *Nat Rev Mol Cell Biol* 3, 430–440.

Wang L and Eastmond DA (2002) Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187. *Environ Mol Mutagen* 39, 348–356.

Wang L, Roy SK and Eastmond DA (2007) Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells. *Mutat Res* 616, 70–82.

Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S et al. (2011) Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. *Clin Cancer Res* 17, 2570–2580.

Wu J and Wei JJ (2013) HMGA2 and high-grade serous ovarian carcinoma. *J Mol Med (Berl)* 91, 1155–1165.

Wu J, Zhang S, Shan J, Hu Z, Liu X, Chen L, Ren X, Yao L, Sheng H, Li L et al. (2016) Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer. *Cancer Lett* 376, 284–292.

Wu Y, Wang KY, Li Z, Liu YP, Izumi H, Uramoto H, Nakayama Y, Ito K and Kohno K (2014) Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction. *J Exp Clin Cancer Res* 33, 112.

Yan H, Tammaro M and Liao S (2016) Collision of trapped topoisomerase 2 with transcription and replication: generation and repair of DNA double-strand breaks with S' adducts. *Genes (Basel)* 7, 32.

Young AR and Narita M (2007) Oncogenic HMGA2: short or small? *Genes Dev* 21, 1005–1009.

Yu H, Lim HH, Tjokro NO, Satriyannah P, Natarajan S, Chew TW, Klonisch T, Goodman SD, Surana U and Droge P (2014) Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells. *Cell Rep* 6, 684–697.

Yu X, Davenport JW, Urtishak KA, Carillo ML, Gosai SJ, Kolaris CP, Byl JAW, Rappaport EF, Osheroff N, Gregory BD et al. (2017) Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci. *Genome Res* 27, 1238–1249.

Zechiedrich EL and Osheroff N (1990) Eukaryotic topoisomerase II recognizes nucleic acid topology by preferentially interacting with DNA crossovers. *EMBO J* 9, 4555–4562.

Zhang T, Zhang Z, Li F, Hu Q, Liu H, Tang M, Ma W, Huang J, Songyang Z, Rong Y et al. (2017) Looping-out mechanism for resolution of replicative stress at telomeres. *EMBO Rep* 18, 1412–1428.

Zhao X, Peter S, Droge P and Yan J (2017) Oncofetal HMGA2 effectively curbs unconstrained (+) and (-) DNA supercoiling. *Sci Rep* 7, 8440.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** HMGA2 protects against DNA damage induced by Etop. (A) HeLa cells were treated with increasing concentrations of Etop for 24 h and their DNA was analyzed by PFGE. (B) H1299 cells (parental and HMGA2 KO cells) were treated with increasing concentrations of Etop for 24 h and their DNA was analyzed by PFGE. (C) HT1080 C1 cells with Dox-regulated HMGA2 expression were treated with increasing concentrations of Etop for 24 h and their DNA was analyzed by PFGE. (D) HT1080 C1 cells with Dox-regulated HMGA2 expression were treated with 10 μM Etop for 24 h and their DNA was analyzed by PFGE (left panel). Quantification of Etop-induced DNA fragments (> 1 Mb and 30–100 kb fractions) (right panel) after normalization with total DNA (n = 3 independent experiments). See section 2.8 for statistical analysis.

**Fig. S2.** HMGA2 protects against DNA damage induced by Merb. (A) H1299 cells (parental and HMGA2 KO cells) treated with decreasing concentrations of Merb for 48 h and their DNA was analyzed by PFGE.